Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 785

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 785
---

CARA THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
(unaudited) The detail of activity related to the Company’s restructuring action is as follows:

| ​ 
 ​ 
 ​ 
 ​ | Total expense recorded in the three months ended March 31, 2024     
 Payments made in the three months ended March 31, 2024              
 Remaining amounts to be paid as of March 31, 2024                   
 Total expense recorded in the three months ended June 30, 2024      | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ |   2,401 
 (1,702) 
     699 
   2,581 | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:--|:--------------------------------------------------------------------|:--|:--|:--|:--|--------:|:--|:--|
| ​ | Payments made in the three months ended June 30, 2024               | ​ | ​ | ​ | ​ |    -301 | ​ | ​ |
| ​ | Remaining amounts to be paid as of June 30, 2024                    | ​ | ​ | ​ | ​ |   2,979 | ​ | ​ |
| ​ | Total expense recorded in the three months ended September 30, 2024 | ​ | ​ | ​ | ​ |     707 | ​ | ​ |
| ​ | Payments made in the three months ended September 30, 2024          | ​ | ​ | ​ | ​ |  -3,400 | ​ | ​ |
| ​ | Remaining amounts to be paid as of September 30, 2024               | ​ | ​ | ​ | $ |     286 | ​ | ​ |

Leases (Original Corporate Headquarters in 2015 & Amendment for Additional Space in 2020) Lease expense was recognized on a straight-line basis over the lease term of the Company’s previous lease agreements for its original headquarters, and additional office space, in Stamford, Connecticut. As a result, $407 and $1,220 of operating lease cost, or lease expense, was recognized for the three and nine months ended September 30, 2023, respectively, consisting of $285 relating to R&D lease expense and $122 relating to G